Company intelligence / Profile preview

Superbio AI

Palo Alto, California, United Statesen.chemlandchem.com ↗

Ownership: Private
Development stage: Commercial

Overview

Superbio AI provides a cloud-based no-code machine learning platform that democratizes access to advanced ML/AI tools for life sciences. The company’s software allows scientists and clinicians to analyze genomics data, single-cell transcriptomics, drug-target interactions, medical images and more without coding expertise. It aggregates public/private datasets and offers out-of-the-box algorithms with GPU acceleration. Recent clinical collaborations include an initiative with Memorial Sloan Kettering Cancer Center to deploy NLP tools for EHR analysis in cancer trials.

Therapeutic areas: OncologyOther
Modalities: Small moleculeMonoclonal antibodyGene therapyRNA therapy
Industry: Drug Discovery Services

Partnerships

Memorial Sloan Kettering Cancer Center (MSK)Academic contributors via marketplace

Beyond the preview

Go deeper on Superbio AI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Superbio AI.

Explore the full profile